Twist Bioscience Corporation (TWST)
TWST trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1581280/000158128025000025/0001581280-25-000025-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | TWST on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001581280 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $376.6M |
| Net income | -$77.7M |
| Operating income | -$136.3M |
| Net margin | -20.6% |
| Operating margin | -36.2% |
| Revenue growth | +20.3% |
| Cash | $183.0M |
| Total assets | $641.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 18.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-03 |
| Cash and burn | $117.4M cash; operating cash flow -$13.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 62,707,424 (2026-07-29); 60,360,925 a year earlier; 57,396,131 three years earlier. | Cover page 2026-07-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2025-12-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $131.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | $118.4M | -$35.1M | $1.1M | $117.4M | No debt tags | $431.8M | 10-Q 2026-08-03 |
| Q2 2026 2026-03-31 | $110.7M | -$44.0M | -$17.6M | $122.7M | No debt tags | $409.5M | 10-Q 2026-05-04 |
| Q1 2026 2025-12-31 | $103.7M | -$30.5M | -$24.8M | $148.6M | No debt tags | $391.6M | 10-Q/A 2026-02-26 |
| Q4 2025 2025-09-30 | $99.0M | -$27.1M | -$11.8M | $183.0M | No debt tags | $376.6M | 10-K 2025-11-17 |
| Q3 2025 2025-06-30 | $96.1M | $20.4M | -$1.4M | $201.4M | No debt tags | $362.3M | 10-Q 2026-08-03 |
| Q2 2025 2025-03-31 | $92.8M | -$39.3M | -$13.0M | $210.4M | No debt tags | $347.7M | 10-Q 2026-05-04 |
| Q1 2025 2024-12-31 | $88.7M | -$31.6M | -$21.4M | $221.4M | No debt tags | $330.2M | 10-Q/A 2026-02-26 |
| Q4 2024 2024-09-30 | $84.7M | -$34.7M | -$15.3M | $226.3M | No debt tags | $313.0M | 10-K 2025-11-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2026-08-19 |
| Latest annual report | 10-K | 2026-11-16 |
| Latest quarterly / interim | 10-Q | 2026-08-03 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-01-06 |
Source: SEC EDGAR submissions feed, 1,017 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.6% |
| 1 month | -26.3% |
| 3 months | -10.9% |
| Year to date | +251.8% |
| 1 year | +273.2% |
| From 52-week high | -45.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMVT | Immunovant Inc. | $33.28 | -2.63% | $6.9B |
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| IBRX | ImmunityBio Inc. | $5.98 | -0.66% | $6.4B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier